Hector Huerga Encabo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hector Huerga Encabo has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
- Dominique Bonnet
Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
17 shared publications - Alessandra Ferrelli
Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
10 shared publications - Gabriella Ficz
Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
10 shared publications - Manuel Garcia-Albornoz
Division of Evolution & Genomic Sciences, University of Manchester, Manchester, UK
10 shared publications - Miriam Llorian-Sopena
The Francis Crick Institute, London, UK
10 shared publications - Alice E. Lord
Centre for Haemato-Oncology, John Vane Science Centre, Charterhouse Square, Barts Cancer Institute, Queen Mary University of London, London, UK
9 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S4. Table S4 provides the complete list of transcription factors activated in human HSPCs from LPS-treated humanized mice.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S4. Table S4 provides the complete list of transcription factors activated in human HSPCs from LPS-treated humanized mice.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S6. Table S6 provides the complete list of differentially accessible transcription factor motifs from the ATAC-Seq analysis.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S6. Table S6 provides the complete list of differentially accessible transcription factor motifs from the ATAC-Seq analysis.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S7. Table S7 provides the list of antibodies used in flow cytometry and FACS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S7. Table S7 provides the list of antibodies used in flow cytometry and FACS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Figure S1. Long term culture competition assays of TET2Mut human HSPCs, related to Figure 1. Figure S2. Transcriptional responses of human HSPCs and its myeloid progeny upon LPS challenge, related to Figure 2. Figure S3. Absence of selective advantage of TET2Mut HSPCs in humanized NBSGW mice, related to Figure 3. Figure S4. In vivo models triggering emergency myelopoiesis are associated with TET2-CH expansion, related to Figure 3. Figure S5. In an in vivo model of systemic inflammation, human TET2Mut HSCs exhibit a dampened transcriptional response, originated from steady-state epigenetic repression of JUN and FOS related to Figure 4. Figure S6. TET2Mut human HSPCs produce a distinct progeny with myeloid cell subsets prompted to produce exacerbated inflammatory response, related to Figure 5. Figure S7. TET2Mut myeloid progeny acquired characteristics of inflamed tissue monocytes and distinct macrophage differentiation, related to Figure 5.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Figure S1. Long term culture competition assays of TET2Mut human HSPCs, related to Figure 1. Figure S2. Transcriptional responses of human HSPCs and its myeloid progeny upon LPS challenge, related to Figure 2. Figure S3. Absence of selective advantage of TET2Mut HSPCs in humanized NBSGW mice, related to Figure 3. Figure S4. In vivo models triggering emergency myelopoiesis are associated with TET2-CH expansion, related to Figure 3. Figure S5. In an in vivo model of systemic inflammation, human TET2Mut HSCs exhibit a dampened transcriptional response, originated from steady-state epigenetic repression of JUN and FOS related to Figure 4. Figure S6. TET2Mut human HSPCs produce a distinct progeny with myeloid cell subsets prompted to produce exacerbated inflammatory response, related to Figure 5. Figure S7. TET2Mut myeloid progeny acquired characteristics of inflamed tissue monocytes and distinct macrophage differentiation, related to Figure 5.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S5. Table S5 provides the complete list of differentially methylated regions between TET2WT and TET2Mut HSPCs.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S5. Table S5 provides the complete list of differentially methylated regions between TET2WT and TET2Mut HSPCs.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S1. Table S1 provides the GSEA of Untreated compared to LPS conditions, related to Figure 2.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S1. Table S1 provides the GSEA of Untreated compared to LPS conditions, related to Figure 2.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S3. Table S3 provides the GSEA of TET2WT compared to TET2Mut cells, related to Figure 2.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S3. Table S3 provides the GSEA of TET2WT compared to TET2Mut cells, related to Figure 2.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S2. Table S2 provides list of differentially expressed genes, related to Figure 2.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Table S2. Table S2 provides list of differentially expressed genes, related to Figure 2.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (2) , 287-305
Human TET2 -Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Clonal hematopoiesis (CH) increases with age and is associated with severe outcome in the course of infections or tumor development. Understanding the environmental conditions that favor mutant clones and the CH immune system response to such environments is key to designing therapeutic strategies to stall the expansion of mutant clones and the development of CH-associated pathologies. Using human cells, we unravel a cell-specific and opposite impact of TET2 mutations on hematopoietic stem and progenitor cells (HSPC) compared with their myeloid progeny. Multi-omic analyses reveal that TET2-mutant HSPCs exhibit intrinsic epigenetic silencing of AP-1 transcription factors and a blunted transcriptional adaptation to systemic inflammation. Conversely, monocyte–macrophage trajectory derived from TET2Mut hematopoietic stem cells (HSC) contributes to exacerbated inflammation. Together, these findings reconcile how TET2-mutant CH can simultaneously promote increased stemness within the HSPC compartment and heightened inflammation through its myeloid progeny, providing mechanistic insight into how TET2-CH expands under inflammatory stress. Significance: This study reveals that stress conditions inducing emergency myelopoiesis expand human TET2-mutant clones. TET2 mutation triggers an epigenetic silencing of AP-1 factors contributing to the dampening of the inflammatory responsiveness in TET2mut HSPCs while simultaneously promoting hyperinflammatory TET2mut monocyte–macrophage activation and differentiation, reinforcing inflammation.
- 3 December 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (2) , 287-305
Open AccessHuman TET2 -Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
Clonal hematopoiesis (CH) increases with age and is associated with severe outcome in the course of infections or tumor development. Understanding the environmental conditions that favor mutant clones and the CH immune system response to such environments is key to designing therapeutic strategies to stall the expansion of mutant clones and the development of CH-associated pathologies. Using human cells, we unravel a cell-specific and opposite impact of TET2 mutations on hematopoietic stem and progenitor cells (HSPC) compared with their myeloid progeny. Multi-omic analyses reveal that TET2-mutant HSPCs exhibit intrinsic epigenetic silencing of AP-1 transcription factors and a blunted transcriptional adaptation to systemic inflammation. Conversely, monocyte–macrophage trajectory derived from TET2Mut hematopoietic stem cells (HSC) contributes to exacerbated inflammation. Together, these findings reconcile how TET2-mutant CH can simultaneously promote increased stemness within the HSPC compartment and heightened inflammation through its myeloid progeny, providing mechanistic insight into how TET2-CH expands under inflammatory stress. Significance: This study reveals that stress conditions inducing emergency myelopoiesis expand human TET2-mutant clones. TET2 mutation triggers an epigenetic silencing of AP-1 factors contributing to the dampening of the inflammatory responsiveness in TET2mut HSPCs while simultaneously promoting hyperinflammatory TET2mut monocyte–macrophage activation and differentiation, reinforcing inflammation.
- Open Access
- 22 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (21) , 2411-2423
Clonal hematopoiesis landscape in frequent blood donors
Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 lifetime donations) to investigate the phenomenon of clonal hematopoiesis (CH). No significant difference in the overall incidence of CH was found in frequent donors (FDs) compared with sporadic donors (<10 lifetime donations; 212 donors). However, upon deeper analysis of mutations in DNMT3A, the most commonly affected gene in CH, we observed distinct mutational patterns between the FD and age/sex-matched control donor cohorts. Functional analysis of FD-enriched DNMT3A variants examined in CRISPR-edited human HSCs demonstrated their competitive outgrowth potential upon stimulation with erythropoietin (EPO), a hormone that increases in response to blood loss. In contrast, clones harboring leukemogenic DNMT3A R882 mutations increase upon stimulation with interferon gamma. Through concurrent mutational and immunophenotypic profiling of primary samples at single-cell resolution, a myeloid bias of premalignant R882 mutant HSCs was found, whereas no significant lineage bias was observed in HSCs harboring EPO-responsive DNMT3A variants. The latter exhibited preferential erythroid differentiation when persistent erythropoietic stress was applied to CRISPR-edited human HSC xenografts. Our data demonstrate a nuanced, ongoing Darwinian evolution at the somatic stem cell level, with EPO identified as a novel environmental factor that favors HSCs carrying certain DNMT3A mutations.
- 22 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (21) , 2411-2423
Open AccessClonal hematopoiesis landscape in frequent blood donors
Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 lifetime donations) to investigate the phenomenon of clonal hematopoiesis (CH). No significant difference in the overall incidence of CH was found in frequent donors (FDs) compared with sporadic donors (<10 lifetime donations; 212 donors). However, upon deeper analysis of mutations in DNMT3A, the most commonly affected gene in CH, we observed distinct mutational patterns between the FD and age/sex-matched control donor cohorts. Functional analysis of FD-enriched DNMT3A variants examined in CRISPR-edited human HSCs demonstrated their competitive outgrowth potential upon stimulation with erythropoietin (EPO), a hormone that increases in response to blood loss. In contrast, clones harboring leukemogenic DNMT3A R882 mutations increase upon stimulation with interferon gamma. Through concurrent mutational and immunophenotypic profiling of primary samples at single-cell resolution, a myeloid bias of premalignant R882 mutant HSCs was found, whereas no significant lineage bias was observed in HSCs harboring EPO-responsive DNMT3A variants. The latter exhibited preferential erythroid differentiation when persistent erythropoietic stress was applied to CRISPR-edited human HSC xenografts. Our data demonstrate a nuanced, ongoing Darwinian evolution at the somatic stem cell level, with EPO identified as a novel environmental factor that favors HSCs carrying certain DNMT3A mutations.